Behavioural supersensitivity following neonatal 6-hydroxydopamine: Attenuation by MK-801

Neurotoxicity Research

Volumn 12, Issue 2, 2007, Pages 113-124

  Archer, Trevor ^a,b   Fredriksson, Anders ^c  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b LINNAEUS UNIVERSITY   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

6 Hydroxydopamine; Apomorphine; Attenuation; Locomotion; MK 801; Neonatal; Rearing; Supersensitivity; Total activity

Indexed keywords

DIZOCILPINE; OXIDOPAMINE; DIZOCILPINE MALEATE; DOPAMINE; NEUROPROTECTIVE AGENT; NORADRENALIN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; LOCOMOTION; MALE; NEWBORN; NONHUMAN; OLFACTORY BULB; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RAT; RECEPTOR SENSITIVITY; SEROTONIN BRAIN LEVEL; ANALYSIS OF VARIANCE; ANIMAL; ANIMAL BEHAVIOR; BRAIN LEVEL; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; DRUG EFFECT; HYPERKINESIA; METABOLISM; MOTOR ACTIVITY; TIME; WISTAR RAT;

MUS; RATTUS;

ANALYSIS OF VARIANCE; ANIMALS; ANIMALS, NEWBORN; BEHAVIOR, ANIMAL; BRAIN CHEMISTRY; DIZOCILPINE MALEATE; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HYPERKINESIS; MALE; MOTOR ACTIVITY; NEUROPROTECTIVE AGENTS; NOREPINEPHRINE; OXIDOPAMINE; RATS; RATS, WISTAR; TIME FACTORS;

EID: 38449086349     PISSN: 10298428     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03033920     Document Type: Article

References (63)

1. Archer T and A Fredriksson (1992) Functional changes implicating dopaminergic systems following perinatal treatments. Dev. Pharmacol. Ther. 18, 201-222.
2. Archer T, A Fredriksson, G Jonsson, T Lewander, AK Mohammed, SB Ross and U Söderberg (1986) Central noradrenergic depletion antagonizes aspects of d-amphetamine-induced hyperactivity in the rat. Psychopharmacology 88, 141-146.
3. Archer T, W Danysz, A Fredriksson, G Jonsson, J Luthman, E Sundström and A Teiling (1988) Neonatal 6-hydroxydopamine-induced dopamine depletions: Motor activity and performance in maze learning. Pharmacol. Biochem. Behav. 31, 357-364.
4. Archer T, RJ Beninger, TUC Järbe and LS Seiden (1990) Latent learning in a radial arm maze following neonatal dopamine depletions. Behav. Pharmacol. 1, 191-199.
5. Archer T, M Bassen, D Peters, J Luthman and A Fredriksson (1996) Dopaminergic-glutamatergic balance in the fore-brain: Functional studies of movement disorders in rats and mice, In: Dopamine Disease States (Beninger RJ, T Palomo and T Archer, Eds.) (Madrid University Press: Madrid), pp. 117-154.
6. Archer T, T Palomo and A Fredriksson (2002a) Functional deficits following neonatal dopamine depletion and isolation housing: Circular water maze acquisition under pre-exposure conditions and motor activity. Neurotox. Res. 4, 503-522.
7. Archer T, T Palomo and A Fredriksson (2002b) Neonatal 6-hydroxydopamine-induced hypo/hyperactivity: Blockade by dopamine reuptake inhibitors and effect of acute D-amphetamine. Neurotox. Res. 4(3), 247-266.
8. Archer T, T Palomo, R McArthur and A Fredriksson (2003) Effects of acute administration of DA agonists on locomotor activity: MPTP versus neonatal intracerebroventricular 6-OHDA treatment. Neurotox. Res. 5, 95-110.
9. Björk L, LJ Cornfield, DI Nelson, SE Hillver and NE Andén (1991) Pharmacology of the novel 5-hydroxytryptamine-1A receptor antagonist (S) -5-flouro-8-hydroxy-2-(dipropyl-amino) tetralin: inhibition of (R) -8-hydroxy-2-(dipropyl-amino)tetralin-induced effects. J. Pharmacol. Exp. Ther. 258, 58-65.
10. Breese GR and RA Mueller (1985) SCH-23390 antagonism of a D-2 dopamine agonist depends upon catecholeaminergic neurons. Eur. J. Pharmacol. 113, 109-114.
11. Breese GR, A Baumeister, TC Napier, GD Frye and RA Mueller (1985) Evidence that D-1 dopamine receptors contribute to the supersensitive behavioural responses induced by L-dihydroxyphenylalanine in rats treated neonatally with 6-hydroxydopamine. J. Pharmacol. Exp. Ther. 235, 287-295.
12. Breese GR, RA Mueller, TC Napier and GE Duncan (1986) Neurobiology of D 1 dopamine receptors after neonatal 6-OHDA treatment: Relevance to Lesch-Nyhan disease. Adv. Exp. Med. Biol. 204, 197-215.
13. Breese GR, HE Criswell, GE Duncan, SS Moy, KB Johnson, DF Wong and RA Mueller (1995) Model for reduced brain dopamine in Lesch-Nyhan syndrome and the mentally retarded: Neurobiology of neonatal 6-hydroxydopamine lesioned rats. Ment. Retard. Dev. Disabil. Res. Rev. 1, 111-119.
14. Breese GR, DJ Knapp, HE Criswell, SS Moy, ST Papadeas and BL Blake (2005) The neonate-6-hydroxydopamine-lesioned rat: A model for clinical neuroscience and neurobiological principles. Brain Res. Rev. 48, 57-73.
15. Buonamici M, C Caccia, M Carpentieri, M Pegrassi, AC Rossi and G Di Chiara (1986) D-1 receptor supersensitivity in the rat striatum after unilateral 6-hydroxydopamine lesions. Eur. J. Pharmacol. 126, 347-348.
16. Carlsson M and A Carlsson (1989a) The NMDA antagonist MK-801 causes marked locomotion stimulation in monoamine-depleted mice. J. Neural Transm. 75, 221-226.
17. Carlsson M and A Carlsson (1989b) Dramatic synergism between MK-801 and clonidine with regard to locomotor stimulatory effect in monoamine-depleted mice. J. Neural Transm. 77, 65-71.
18. Carlsson M and A Svensson (1990) Interfering with glutamatergic neurotransmission by means of NMDA antagonist administration discloses the locomotor stimulatory potential of other transmitter systems. Pharmacol. Biochem. Behav. 36, 45-50.
19. Carlsson M, A Svensson and A Carlsson (1991) Synergistic interactions between muscarinic antagonists, adrenergic agonists and NMDA antagonists with respect to locomotor stimulatory effects in monoamine-depleted mice. Naunyn-Schmiedebergs Arch. Pharmacol. 343, 568-573.
20. Chase TN, F Bibbiani and JD Oh (2003) Striatal glutamatergic mechanisms and extrapyramidal movement disorders. Neurotox. Res. 5, 139-146.
21. Concannon JT and MD Schechter (1981) Hyperactivity in developing rats: sex differences in 6-hydroxydopamine and amphetamine effects. Pharmacol. Biochem. Behav. 14, 5-10.
22. Creese I and SD Iversen (1973) Blockade of amphetamine-induced motor stimulation and stereotypy in the adult rat following neonatal treatment with 6-hydroxydopamine. Brain Res. 55, 369-382.
23. Criswell HE, RA Mueller and GR Breese (1990) Long-term D-1-dopamine receptor sensitization in neonatal 6-hydroxydopamine-lesioned rats is blocked by an NMDA antagonist. Brain Res. 512, 284-290.
24. Criswell HE, KB Johnson, RA Mueller and GR Breese (1993) Evidence for involvement of brain dopamine and other mechanisms in the behavioural action of the N -methyl-D-aspartic acid antagonist MK-801 in control and 6-hydroxydopamine-lesioned rats. J. Pharmacol. Exp. Ther. 265, 1001-1010.
25. Eastgate SM, JJ Wright and JS Werry (1978) Behavioural effects of methylphenidate in 6-hydroxydopaminetreated neonatal rats. Psychopharmacology 58, 157-159.
26. Erinoff L, RC MacPhail, A Heller and LS Seiden (1979) Age dependent effects of 6-hydroxydopamine on locomotor activity in the rat. Brain Res. 164, 195-205.
27. Fuxe K, BB Fredholm, LF Agnati, SO Ögren, BJ Everitt, G Jonsson and JÅ Gustafsson (1978a) Interaction of ergot drugs with central monoamine systems: Evidence for a high potential in the treatment of mental and neurological disorders. Pharmacology 16 (Suppl. 1), 99-134.
28. Fuxe K, BB Fredholm, SO Ögren, LF Agnati, T Hökfelt and JÅ Gustafsson (1978b) Ergot drugs and central monoaminergic mechanisms: A histochemical, biochemical and behavioural analysis. Fed. Proc. 37, 2181-2191.
29. Karler R, LD Calder, IA Chaudhry and SA Turkanis (1989) Blockade of "reverse tolerance" to cocaine and amphetamine by MK-801. Life Sci. 45, 599-606.
30. Kirk RE (1995) Experimental Design: Procedures for the Behavioural Sciences (Brooks/Cole: Belmont, CA).
31. Klockgether T, L Turski, T Honore, Z Zhang, DM Gash, R Kurlan and T Greenamyre (1991) The AMPA receptor antagonist NBQX has antiparkinsonian effects in monoaminedepleted rats and MPTP-treated monkeys. Ann. Neurol. 30, 717-723.
32. Kostrzewa RM (1995) Dopamine receptor supersensitivity. Neurosci. Biobehav. Rev. 19, 1-17.
33. Kostrzewa RM (2003) Dopamine receptor supersensitivity: An outcome and index of neurotoxicity. Neurotox. Res. 5, 111-118.
34. Kostrzewa RM and A Hamdi (1991) Potentiation of spiperone-induced oral activity in rats after neonatal 6-hydroxydopamine. Pharmacol. Biochem. Behav. 38, 215-218.
35. Kostrzewa RM, R Brus, KW Perry and RW Fuller (1993) Age dependence of a 6-hydroxydopamine lesion on SKF 38393- and m -chlorophenylpiperazine-induced oral activity responses of rats. Brain Res. Dev. Brain Res. 76, 87-93.
36. Kronthaler UP, M Bubser and WJ Schmidt (1994) Behavioural functions of the mesostriatal system as revealed by 6-OHDA lesions in the striatum of rats. Proc. 22nd Göttingen Neurobiol. Conf. P. 761.
37. Lieberman A, T Miyamoto, A Battista and M Goldstein (1975) Studies on the antiparkinsonian efficacy of lergotrile. neurology 25, 459-462.
38. Lieberman A, M Zolfaghari, D Boal, H Hassouri, B Vogel, A Battista, K Fuxe and M Goldstein (1976) The antiparkinsonian efficacy of bromocriptine. Neurology 26, 405-409.
39. Lieberman A, M Goldstein, G Gopinathan and A Neophyrides (1987) D-1 and D-2 agonists in Parkinson's disease. Can. J. Neurol. Sci. 14, 466-473.
40. 2-receptor antagonists. J. Med. Chem. 38, 150-160.
41. Luthman J, B Bolioli, T Tsutsumi, A Verhofstad and G Jonsson (1987) Sprouting of striatal serotonin nerve terminals following selective lesions of nigro-striatal dopamine neurons in neonatal rat. Brain Res. Bull. 19, 269-274.
42. Luthman J, A Fredriksson, T Lewander, G Jonsson and T Archer (1989a) Effects of d-amphetamine and methylphenidate on hyperactivity produced by neonatal 6-hydroxydopamine treatment. Psychopharmacology 99, 550-557.
43. Luthman J, A Fredriksson, E Sundström, G Jonsson and T Archer (1989b) Selective lesion of central dopamine or noradrenaline systems in the neonatal rat: Motor behaviour and monoamine alterations at adult stage. Behav. Brain Res. 33, 267-277.
44. Luthman J, A Fredriksson, A Plaznik and T Archer (1991) Ketanserin and mianserin treatment reverses hyperactivity in neonatally dopamine lesioned rats. J. Psychopharmacol. 5, 418-425.
45. Luthman J, E Lindqvist and SO Ögren (1995) Hyperactivity in neonatally dopamine-lesioned rats depends on residual activity in mesolimbic dopamine neurons. Pharmacol. Biochem. Behav. 51, 159-163.
46. Luthman J, M Bassen, A Fredriksson and T Archer (1997) Functional changes induced by 6-hydroxydopamine lesions: Effects of dose levels on behavioural parameters. Behav. Brain Res. 82, 213-221.
47. Miller FE, TG Heffner, C Kotake and LS Seiden (1981) Magnitude and duration of hyperactivity following neonatal 6-hydroxydopamine is related to brain dopamine depletion. Brain Res. 229, 123-132.
48. 2 responses in the 6-hydroxydopamine model of Parkinson's disease. Eur. J. Pharmacol. 182, 611-612.
49. 2 -mediated behaviour in 6-hydroxydopamine model of turning: Relationship with c-fos expression. J. Pharmacol. Exp. Ther. 260, 402-408.
50. Moy SS and GR Breese (2002) Phencyclidine supersensitivity in rats with neonatal dopamine loss. Psychopharmacology 161, 255-262.
51. Moy SS, HE Criswell and GR Breese (1997) Differential effects of bilateral dopamine depletion in neonatal and adult rats. Neurosci. Biobehav. Rev. 21, 425-435.
52. Ohno M, H Yoshida and S Watanabe (1994) NMDA receptor-mediation expression of Fos protein in the rat striatum following methamphetamine administration: Relation to behavioural sensitization. Brain Res. 665, 135-140.
53. Palomo T, RJ Beninger, RM Kostrzewa and T Archer (2006) Co-morbidity implications in brain disease: Neuronal substrates of symptom profiles. Neurotox. Res. 10, 1-13.
54. Porter RHP and JT Greenemyre (1995) Regional variations in the pharmacology of NMDA receptor channel blockers: Implications for therapeutics potential. J. Neurochem. 64, 614-623.
55. Roehrich H, CA Dackis and MS Gold (1987) Bromocriptine. Med. Res. Rev. 7, 243-269.
56. 2 agonists in squirrel monkeys. Psychopharmacology 116, 9-18.
57. 2 receptor activation. Life Sci. 40, 2461-2471.
58. Shaywitz BA, HH Klopper, RD Yager and JW Gordon (1976) Paradoxical response to amphetamine in developing rats treated with 6-hydroxydopamine. Nature 261, 153-155.
59. Sorensen CA, JS Vayer and CS Goldberg (1977) Amphetamine reduction of motor activity in rats after neonatal administration of 6-hydroxydopamine. Biol. Psychiatry 12, 133-137.
60. Svensson A and M Carlsson (1991) Injection of the competitive NMDA receptor antagonist AP-5 into the nucleus accumbens of monoamine-depleted mice induces pronounced locomotor stimulation. Neuropharmacology 31, 513-518.
61. Wolf ME (1998) The role of excitatory amino acids in behavioural sensitization to psychomotor stimulants. Prog. Neurobiol. 54, 679-720.
62. Wolf ME and M Jeziorski (1993) Coadministration of MK-801 with amphetamine, cocaine or morphine prevents rather than transiently masks the development of behavioural sensitization. Brain Res. 613, 291-294.
63. Zhang K, FI Tarazi and RJ Baldessarini (2001) Role of dopamine(4) receptors in motor hyperactivity induced by neonatal 6-hydroxydopamine lesions. Neuropsychopharm-acology 25, 624-632.